ClinicalTrials.gg
Active, not recruitingNCT06541938AIRE-2Updated Nov 17, 2026

AIRE-2 Device for Study of Breath Analysis in IBD

An interventional study of low FODMAP diet and Lactose Sachet in Inflammatory Bowel Diseases, sponsored by McMaster University. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by McMaster University · Not applicable, Interventional, and Screening

How we know

Updated Nov 17, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 156 studies in Inflammatory Bowel Diseases with a site in Canada — 35 open to participants now, 50 under way, 6 of them phase 3. Inflammatory Bowel Diseases · Canada.

Enrollment
88th of 119
57 · median 120
Started
2024
with 12 others
No phase
46 of 156
12 open now
Primary completion
2026-11
later than 17 of 49 live
Registered
132nd of 156
by date
Lead sponsor
7 of 156
McMaster University

Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, this one is the 88th largest by enrollment of the 119 interventional ones that give a count, is one of 13 that started in 2024, is one of 46 with no phase, reaches primary completion later than 17 of the 49 other live ones, and was the 132nd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

35 of the 156 studies in Inflammatory Bowel Diseases with a site in Canada are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Inflammatory Bowel Diseases with a site in Canada, or all of them as a file.
02

Study summary

The goal of this Prospective single-blinded intervention feasibility study is the utilization of the AIRE-2 device and FoodMarble app to elucidate the interplay among diet, symptoms, and microbial fermentable features in IBD patients with persistent intestinal symptoms and non-IBD controls.

AIRE-2 captures exhaled hydrogen and methane and FoodMarble app records breath levels, symptoms and dietary intake.

The main questions it aims to answer are:

  1. To assess the feasibility of using the AIRE-2 device, FoodMarble mobile app in a cohort of IBD patients and non-IBD controls to collect data on diet, symptoms and exhaled H2 and CH4 levels. 2.
  2. To assess the feasibility of using FoodMarble's FODMAP discovery kit protocol in a cohort of IBD patients and non-IBD controls.
  3. To collect preliminary data on the relation between diet, symptoms, and exhaled H2 and CH4 levels measured by the AIRE-2 device and FoodMarble app in a cohort of IBD patients and non-IBD controls.
  4. To explore the correlation between the fecal metagenomic profile with exhaled H2 and CH4 levels, diet and symptoms in a cohort of IBD patients and non-IBD controls.

You will:

  1. Record regular diet in the FoodMarble app and collect baseline stool samples
  2. You will then take a low FODMAP diet for 24 hours every week and if willing will be required to record the diet and symptoms. After the diet, you will take the FODMAP challenge of Lactose, Fructose, Sorbitol and Inulin (one every week) using Sachets provided by FoodMarble company, record exhaled breath levels, symptoms and collect stool. This process will take 4 weeks.
  3. Visit clinic to submit stool samples
Read the detailed description

Study Design Type:

Prospective single-blinded intervention feasibility study

Methodology/Study Design:

A cohort of IBD patients and non-IBD controls will be recruited for this study. You will be instructed to use a handheld breathalyzer device, AIRE-2, to measure exhaled H2 and CH4 gas production, and its smartphone app, FoodMarble, will be used to log your diet and symptoms for a period of 5 weeks, as follows:

AIRE-2 will be used before and after two meals each day - the first meal and the last meal of the day. You will breathe into the AIRE-2 device before eating to obtain the baseline value. After the meal, you will breathe into the AIRE-2 60 minutes postprandially. The exhaled H2 and CH4 measurements will be automatically logged into the FoodMarble app, which is connected via Bluetooth. You will log your food intake and symptoms in FoodMarble. Symptoms scores will be recorded at the same time that the AIRE- 2 device is being used - 60 minutes postprandial. You will be asked not to drink alcohol during the meals that will be recorded, as this will skew the device results. You will be informed that you can consume alcoholic drinks after doing the postprandial breath test.

Study procedure:

  1. Study Enrolment and Familiarization Period: At visit 1, you will be trained to use the AIRE-2 device which McMaster has purchased from the FoodMarble company and will be provided to you. You will also be trained to use the FoodMarble app. The FoodMarble company is the owner of the AIRE-2 device which is being used in the present study, the company wouldn't have access to resulting data other than publication. Demographics, medical history, disease activity, Gastrointestinal symptom rating scale (GSRS), Bristol stool type, medications, supplements, perceived food intolerances and general dietary patterns will be recorded at baseline. We shall assist you in inputting some GI and extra-intestinal symptoms (headache, foggy mind, numbness of joints, joint pain, fainting, oral lesions, dermatitis) manually in the FoodMarble app from the GSRS symptom questionnaire as all symptoms are not mentioned in the app and there is a provision to edit the symptom list. After visit 1, you will have 3 days to use the device and app in order to become familiar with its use and report any challenges and difficulties to us in visit 2 (online via McMaster Zoom). At the end of the familiarization period, you are expected to be comfortable using the AIRE-2 device and the FoodMarble app. No data reported during this period will be used for the purpose of analysis or outcomes evaluation.
  2. Baseline Period: This period starts after the familiarization week and runs for one week, representing the beginning of the data tracking collection. During the baseline period, you will eat your normal, typical diet, while collecting your breath test, food and symptoms as described above. The baseline period serves to capture the natural fluctuations of breath H2 and CH4 of each individual and to explore the correlations with diet and symptoms. You will be instructed to take the breath test before and 60 minutes after two major meals, every day. You will also collect the baseline stool sample and drop it off at the study location during visit 3, at the end of this period. You will be handed the low FODMAP diet chart which will be required in discovery period.
  3. Discovery Period: This period starts after the baseline period and runs for four weeks. During this period, you will document your responses to challenges with four specific FCHOs)- Lactose, Fructose, Sorbitol, and Inulin ("Food Intolerance Kit", FoodMarble Inc, Dublin, Ireland). The quantities of each FCHO challenge are as follows: lactose and fructose sachets, 25g each. A sachet of lactose roughly equal to amount of lactose present in 1 large glass of milk. A sachet of fructose is roughly equal to amount of fructose present in 2 large apples. Sorbitol and inulin sachets contain 10g each. A sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune. A sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic. Each sachet has to be dissolved in 250 ml of lukewarm water. Before each challenge, you will follow a low FODMAP diet for 24h to facilitate clearance of any FCHOs from the intestine. You will be guided by a registered dietitian (RD) regarding an appropriate low FCHO diet, supported by the FoodMarble app, which provides a large database of low FODMAP meals and recipes. You will log all meals during the 24h low FCHO period using the FoodMarble app (optional). The meals will be analyzed by the RD and scored, on a 4-point scale (poor, moderate, good, excellent) for adherence to the low FCHO diet. Exhaled H2 and CH4 will be measured before and 60 min after the first and last meal during this period, as usual. After the 24h low FCHO diet, you will consume one FCHO challenge in the morning (after the baseline breath test) and take the postprandial breath test 60 min later (optional). You will be required to record the breath test for 3 hours after every 15 minutes as per the protocol of the kit. You will then collect the first stool sample after the challenge and submit it to us in visit 4. Symptoms and meals will continue to be logged in the FoodMarble app. You will also be instructed to fill in a validated questionnaire to assess symptoms before and after the FCHO challenge (Adult Carbohydrate Perception Questionnaire). This questionnaire will be given to you in paper form. A 6-day washout period will be implemented in between the FCHO challenges. During the washout period, you will follow your typical diet. The 24h low Fodmap day, FCHO challenge, 6-day washout cycle and submission of stool samples (visit 4-7) will be repeated until all 4 FCHO challenges have been completed. The order of the FCHO challenges will be randomized and will be kept constant between all of you to minimize potential co-founding factors related to the order of the intervention. However, you will be blinded to the order.
  4. End of the study: At the end of the discovery period, you will answer a feedback survey to report their experience using AIRE-2 and FoodMarble.
03

Conditions studied

  • Inflammatory Bowel Diseases
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria (IBD):

  • Age 18-75 years old, confirmed diagnosis of IBD (UC or CD)
  • Under clinical remission for at least 3 months
  • Report having one or more IBS-like symptom (abdominal pain, altered bowel habit, flatulence, abdominal distension etc)
  • Own a smartphone with Bluetooth capability
  • Fluent in English.
  • Able to understand the instructions to use smartphone apps
  • Able to provide

Exclusion criteria (IBD):

  • Use of antibiotics 1 month before enrolment
  • Active IBD (disease activity score, fecal calprotectin, CRP)
  • Presence of a stoma
  • Pregnancy
  • Type 1 diabetes or insulin-dependent Type 2 diabetes
  • Currently being treated for eating disorder, schizophrenia, psychosis or other acute mental disorder

A total of 30 adult IBD patients (18-75 years old), 15 ulcerative colitis (UC) and 15 Crohn's disease (CD) patients, will be recruited at the Digestive Diseases Clinic, McMaster University, Hamilton, Ontario.

Controls: A total of 30 non-IBD volunteers from the same household as the recruited IBD patients or the general population who do not have any IBS-like symptoms will be recruited as controls.

Inclusion criteria:

  • Age 18-75 years old, IBS-negative (Rome IV negative)
  • Asymptomatic
  • Own a smartphone with Bluetooth capability
  • Fluent in English.
  • Able to understand the instructions to use smartphone apps
  • Able to provide informed consent

Exclusion criteria:

  • Diagnosed with IBD or other Gastrointestinal disorder
  • Use of antibiotics 1 month before enrolment
  • Pregnancy
  • Type 1 diabetes or insulin-dependent Type 2 diabetes
  • Currently being treated for eating disorder, schizophrenia, psychosis or other acute mental disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Case - Inflammatory Bowel Disease

    Patients with IBD, under clinical remission since more than 3 months, having at least one symptom

    Dietary Supplement: low FODMAP diet · Dietary Supplement: Lactose Sachet · Dietary Supplement: Fructose Sachet · Dietary Supplement: Sorbitol Sachet · Dietary Supplement: Inulin Sachet · Device: AIRE-2 Portable breath analyzer

  • Active comparator
    Control - Non-IBD (Healthy) Control

    Non-IBD controls recruited from the household or general population, with no history of IBD or active gastrointestinal disease.

    Dietary Supplement: low FODMAP diet · Dietary Supplement: Lactose Sachet · Dietary Supplement: Fructose Sachet · Dietary Supplement: Sorbitol Sachet · Dietary Supplement: Inulin Sachet · Device: AIRE-2 Portable breath analyzer

Interventions

  • Dietary supplementlow FODMAP diet

    You consume low FODMAP diet for 24 hours before taking the FODMAP challenge

  • Dietary supplementLactose Sachet

    You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. 25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk

  • Dietary supplementFructose Sachet

    You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. 25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples

  • Dietary supplementSorbitol Sachet

    You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. 10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune

  • Dietary supplementInulin Sachet

    You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors. A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic

  • DeviceAIRE-2 Portable breath analyzer

    The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge

06

What researchers measure

Primary outcomes

  1. Proof of data collection/Adherence to the protocol

    For each data set, we will divide the number of logged data divided by the total data expected to be logged. For example, the number of breath tests using AIRE-2 logged by the participant / total expected. This will also apply to the diet log. The results will be expressed in %.

    Time frame: 40 months

Secondary outcomes

  1. Comparison of positive breath between IBD and non-IBD controls

    average of # \>3 breath test score / total group #

    Time frame: 40 months

  2. Prevalence of positive score with symptoms between IBD and non-IBD controls

    \# of events when \>3 breath test score match with symptomatic event / total positive test events

    Time frame: 40 months

  3. Correlation of positive breath tests with severity of symptoms

    using person correlation coefficient

    Time frame: 40 months

  4. Correlation of breath scores with food reported as being intolerant by the participants

    matching between reported dietary triggers at baseline and positive breath test

    Time frame: 40 months

  5. Microbiome taxa

    We will explore the associations between fecal microbiome taxa and exhaled H₂ and CH₄ levels. The microbiome profile will be characterized using shotgun metagenomic sequencing of fecal samples.

    Time frame: 40 months

  6. Relative abundance of microbial metabolic pathways

    Microbial metabolic pathways and functional profiles will be characterized using shotgun metagenomic sequencing and correlated with dietary intake, exhaled H₂ and CH₄ levels, and symptom patterns.

    Time frame: 40 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Nov 2026, 26 months.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 26 months is close to that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Nov 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Aug 7, 2024
StartActual
Aug 28, 2024
Primary completionActual
Nov 2, 2026was Sep 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Primary completion
Sep 30, 2027→Nov 2, 2026 (actual)
Nov 17, 2026
Enrollment
60 (estimated)→57 (actual)
Nov 17, 2026
Eligibility
1 criterion edited, 2 removed
What changed in the criteria
  • RemovedHistory of bowel resection
  • EditedControls: A total of 30 non-IBD volunteers from the same household as the recruited IBD patients or the general population who do not have any IBS-like symptomsymptoms will be recruited as controls.
  • RemovedLiving in the same household as IBD patients, sharing a similar diet
Nov 17, 2026
Interventions
Arm changed Control - Healthy household member→Control - Non-IBD (Healthy) Control
Nov 17, 2026
Secondary outcomes
4 edited, 1 description edited
What changed in the outcomes
  • EditedComparison of positive breath between IBD and non-IBD patientscontrolsTime frame: 40 months
  • EditedPrevalence of positive score with symptoms between IBD and non-IBD patientscontrolsTime frame: 40 months
  • EditedCorrelation of breath scores with food reported as being intolerant by the patientsparticipantsTime frame: 40 months
  • EditedRelative abundance of predicted microbial metabolic pathwaysTime frame: 40 months
  • DescriptionMicrobiome taxa: how it is measured was reworded
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 30, 2027→Nov 2, 2026 (now actual)
    Enrollment 60 (estimated)→57 (actual)
    Eligibility 1 criterion edited, 2 removed
    What changed in the criteria
    • RemovedHistory of bowel resection
    • EditedControls: A total of 30 non-IBD volunteers from the same household as the recruited IBD patients or the general population who do not have any IBS-like symptomsymptoms will be recruited as controls.
    • RemovedLiving in the same household as IBD patients, sharing a similar diet
    Secondary outcomes 4 edited, 1 description edited
    What changed in the outcomes
    • EditedComparison of positive breath between IBD and non-IBD patientscontrolsTime frame: 40 months
    • EditedPrevalence of positive score with symptoms between IBD and non-IBD patientscontrolsTime frame: 40 months
    • EditedCorrelation of breath scores with food reported as being intolerant by the patientsparticipantsTime frame: 40 months
    • EditedRelative abundance of predicted microbial metabolic pathwaysTime frame: 40 months
    • DescriptionMicrobiome taxa: how it is measured was reworded
    Interventions Arm changed Control - Healthy household member→Control - Non-IBD (Healthy) Control
    + 6 other changes: identifiers, verification date, oversight details, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06541938
Responsible party
David Armstrong (Professor, McMaster University) — Principal investigator
First posted
Aug 7, 2024
Start date
Aug 28, 2024
Primary completion
Nov 2, 2026
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

David Armstrong
principal investigator · McMaster University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion